SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-016644
Filing Date
2022-08-11
Accepted
2022-08-11 07:31:34
Documents
77
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q fulc-20220630.htm   iXBRL 10-Q 3326972
2 EX-31.1 fulc-ex31_1.htm EX-31.1 16076
3 EX-31.2 fulc-ex31_2.htm EX-31.2 19629
4 EX-32.1 fulc-ex32_1.htm EX-32.1 8819
5 EX-32.2 fulc-ex32_2.htm EX-32.2 8950
  Complete submission text file 0000950170-22-016644.txt   10690731

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fulc-20220630_pre.xml EX-101.PRE 368348
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT fulc-20220630_def.xml EX-101.DEF 245887
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fulc-20220630_lab.xml EX-101.LAB 458080
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT fulc-20220630_cal.xml EX-101.CAL 46582
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fulc-20220630.xsd EX-101.SCH 58681
71 EXTRACTED XBRL INSTANCE DOCUMENT fulc-20220630_htm.xml XML 2069126
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38978 | Film No.: 221153704
SIC: 2834 Pharmaceutical Preparations